JP6254088B2 - 置換ビアリールアルキルアミド - Google Patents

置換ビアリールアルキルアミド Download PDF

Info

Publication number
JP6254088B2
JP6254088B2 JP2014535990A JP2014535990A JP6254088B2 JP 6254088 B2 JP6254088 B2 JP 6254088B2 JP 2014535990 A JP2014535990 A JP 2014535990A JP 2014535990 A JP2014535990 A JP 2014535990A JP 6254088 B2 JP6254088 B2 JP 6254088B2
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
formula
compound according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014535990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500795A (ja
JP2015500795A5 (enExample
Inventor
カイル ダブリュー.エイチ. チャン,
カイル ダブリュー.エイチ. チャン,
フランク メルキューリオ,
フランク メルキューリオ,
デイビッド アイ. スターリング,
デイビッド アイ. スターリング,
Original Assignee
バイオセリックス, インコーポレイテッド
バイオセリックス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオセリックス, インコーポレイテッド, バイオセリックス, インコーポレイテッド filed Critical バイオセリックス, インコーポレイテッド
Publication of JP2015500795A publication Critical patent/JP2015500795A/ja
Publication of JP2015500795A5 publication Critical patent/JP2015500795A5/ja
Application granted granted Critical
Publication of JP6254088B2 publication Critical patent/JP6254088B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2014535990A 2011-10-17 2012-10-16 置換ビアリールアルキルアミド Expired - Fee Related JP6254088B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548076P 2011-10-17 2011-10-17
US61/548,076 2011-10-17
PCT/US2012/060464 WO2013059215A1 (en) 2011-10-17 2012-10-16 Substituted biaryl alkyl amides

Publications (3)

Publication Number Publication Date
JP2015500795A JP2015500795A (ja) 2015-01-08
JP2015500795A5 JP2015500795A5 (enExample) 2015-12-03
JP6254088B2 true JP6254088B2 (ja) 2017-12-27

Family

ID=47148954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535990A Expired - Fee Related JP6254088B2 (ja) 2011-10-17 2012-10-16 置換ビアリールアルキルアミド

Country Status (8)

Country Link
US (3) US8822527B2 (enExample)
EP (1) EP2768799B1 (enExample)
JP (1) JP6254088B2 (enExample)
CN (1) CN104011013B (enExample)
AU (1) AU2012326361B2 (enExample)
CA (1) CA2850987C (enExample)
MX (2) MX360188B (enExample)
WO (1) WO2013059215A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012326361B2 (en) 2011-10-17 2017-08-03 Biotheryx, Inc. Substituted biaryl alkyl amides
WO2016199688A1 (ja) * 2015-06-10 2016-12-15 住友化学株式会社 カーバメート化合物の製造方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3661946A4 (en) * 2017-08-01 2021-04-21 Agency for Science, Technology and Research PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
CN107540574B (zh) * 2017-09-19 2021-06-11 成都西岭源药业有限公司 R-联苯丙氨醇的制备方法
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CN112312904B (zh) 2018-04-16 2025-01-07 C4医药公司 螺环化合物
CN109053495B (zh) * 2018-07-23 2021-05-28 江苏宇田医药有限公司 一种lcz696中间体的合成方法
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
US20250281433A1 (en) * 2020-12-25 2025-09-11 Amtixbio Co., Ltd. Novel derivative compound having biphenyl group introduced into amino-alkanoic acid and anti-inflammatory composition comprising same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502690B1 (en) 1991-03-05 1999-12-01 Ajinomoto Co., Inc. Cyclopropane derivative
JPH10101655A (ja) 1996-10-01 1998-04-21 Sumitomo Chem Co Ltd オキサゾリン類、その製造法およびそれを用いるスレオ−3−芳香族セリン類の製造法
JPH10101656A (ja) 1996-10-01 1998-04-21 Sumitomo Chem Co Ltd オキサゾール化合物の製造法
ES2253826T3 (es) 1997-09-09 2006-06-01 Duke University Prostaglandinas aromaticas tetrahidro sustituidas por c16-c20 utilizadas como agonistas fp.
US6239134B1 (en) 1999-03-03 2001-05-29 American Home Products Corp. Diazole derivatives as serotonergic agents
ES2220422T3 (es) 1999-03-03 2004-12-16 Wyeth Nuevos derivados de diazol como agentes serotonergicos.
US7022730B2 (en) 2001-10-19 2006-04-04 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
ITRM20020016A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
CA2531796A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
AU2004283147A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7795448B2 (en) 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
WO2006015279A1 (en) 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
US7618983B2 (en) 2004-11-10 2009-11-17 Janssen Pharmaceutica, N.V. Bicyclic triazole α4 integrin inhibitors
US20080175795A1 (en) 2005-06-30 2008-07-24 Bexel Pharmaceuticals, Inc. Novel derivatives of amino acids for treatment of obesity and related disorders
US7399786B2 (en) 2005-06-30 2008-07-15 Bexel Pharmaceuticals, Inc. Derivatives of amino acids for treatment of obesity and related disorders
JP2009511589A (ja) 2005-10-12 2009-03-19 エラン ファーマシューティカルズ,インコーポレイテッド アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
JP2009515964A (ja) 2005-11-16 2009-04-16 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのβ−セクレターゼ阻害剤として有用なイミダゾリジノン化合物
US8017378B2 (en) 2006-01-17 2011-09-13 Sumitomo Chemical Company, Limited Method for production of optically active biphenylalanine compound or salt or ester thereof
US8980833B2 (en) * 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
HRP20110650T1 (hr) 2007-07-27 2011-10-31 Sanofi DERIVATI 1,2,3,4-TETRAHIDROPIROLO[1,2-a]PIRAZIN-6-KARBOKSAMIDA I 2,3,4,5-TETRAHIDROPIROLO[1,2-a]DIAZEPIN-7-KARBOKSAMIDA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
US20100022767A1 (en) 2008-07-25 2010-01-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Development of a synthesis of syringolin a and b and derivatives thereof
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
CN101555211B (zh) 2009-05-13 2012-01-25 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的化学合成方法
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
EP2491006A1 (en) 2009-10-21 2012-08-29 Glaxo Group Limited Process for preparing a phenylalanine derivative
US8575170B2 (en) * 2010-02-26 2013-11-05 The Regents Of The Unversity Of Colorado, A Body Corporate Flurbiprofen analogs and methods of use in treating cancer
DK2651896T3 (en) * 2010-12-15 2015-10-05 Theravance Biopharma R & D Ip Llc Neprilysininhibitorer
AU2012326361B2 (en) 2011-10-17 2017-08-03 Biotheryx, Inc. Substituted biaryl alkyl amides

Also Published As

Publication number Publication date
CN104011013A (zh) 2014-08-27
US20170114006A1 (en) 2017-04-27
JP2015500795A (ja) 2015-01-08
US8822527B2 (en) 2014-09-02
CA2850987C (en) 2019-10-15
EP2768799B1 (en) 2019-08-07
MX2014004503A (es) 2015-01-16
US9546131B2 (en) 2017-01-17
CA2850987A1 (en) 2013-04-25
US10106491B2 (en) 2018-10-23
CN104011013B (zh) 2018-09-21
EP2768799A1 (en) 2014-08-27
AU2012326361A1 (en) 2014-04-17
AU2012326361B2 (en) 2017-08-03
US20130102649A1 (en) 2013-04-25
US20140336235A1 (en) 2014-11-13
WO2013059215A1 (en) 2013-04-25
MX360188B (es) 2018-10-24
HK1201516A1 (en) 2015-09-04

Similar Documents

Publication Publication Date Title
JP6254088B2 (ja) 置換ビアリールアルキルアミド
EP3409276B1 (en) Ire-1a inhibitors
JP2020528918A (ja) アンドロゲン受容体の標的化分解のための化合物および方法
CA3196526A1 (en) Malt-1 modulators
WO2020014489A2 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
JP2022540333A (ja) Bcl-2タンパク質阻害剤
CA3207590A1 (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
CA2824460A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
JP6858252B2 (ja) ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用
US20250214980A1 (en) Multicyclic compounds
WO2012037351A1 (en) Compounds
CA2991168C (en) Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
WO2012037349A2 (en) Compounds
WO2022133069A1 (en) Peptidomimetic matriptase 2 inhibitors and uses thereof
HK1201516B (en) Substituted biaryl alkyl amides
RU2818822C1 (ru) Макроциклическое соединение
WO2024092185A1 (en) Acyl sulfonamide compounds as inhibitors of polyomavirus
WO2025010326A2 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms
CA3194090A1 (en) Macrocyclic compound
HK1179171A (en) Ire-1 inhibitors
HK1179171B (en) Ire-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160829

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160829

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171129

R150 Certificate of patent or registration of utility model

Ref document number: 6254088

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees